Liver cancer incidence has more than tripled since 1980. It is the fifth most commonly occurring cancer in men and the ninth in women. There were over 840,000 new cases in 2018, with a constant increase of almost a 3% per year since 2000.
In the EU27 in 2018, there were 66,869 new liver cancer cases diagnosed. According to the World Health Organisation, over 47,000 Europeans die of liver cancer each year. It is one of the fastest rising of all types of cancers in Canada, having still a higher incidence in the US with 70,000 cases diagnosed with primary liver cancer adults in 2018. In Central and South America the incidence of liver cancer has experienced a huge growth, with an average of 69,048 new HCC patients every year and 28,341 deaths annually. Incidence is substantially higher in Africa and Asia, in some cases being the most frequent form of cancer.
Hepatocellular carcinoma (HCC) is the primary liver malignancy (3 of 4 total liver cancers are HCC). It is typically diagnosed late in its course, with a 5-year survival rate of only 10%. Despite advances in prevention techniques, screening, and new technologies in both diagnosis and treatment, HCC is one of the fastest growing causes of death among all cancers and the second cause of death by cancer worldwide. In addition to the loss of lives and life quality, it poses a major economic burden on healthcare.
HepatoPredictä is an in vitro diagnostic test that supports the clinical decision of liver transplantation in hepatocellular carcinoma (HCC). A molecular signature is integrated with clinical parameters into a predictive algorithm that estimates the risk of HCC recurrence after a liver transplant. It is based on a gene expression expression signature, measured by a real-time PCR assay, of 4 target genes and 3 housekeeping genes, and clinical parameters combined into a computational algorithm, that can predict the good outcome of the intervention with a successful-curative rate of 92.
The test is performed in HCC biopsies and is intended to be exclusively used in RNA samples extracted from formalin-fixed paraffin-embedded (FFPE) HCC tissue and should be only used with the provided reagents and software.
HepatoPredict is aimed at being useful for the tumour board to assess wether a patient with HepatoCellular Carcinoma will benefit from a liver transplantation or any other surgical approach.
HepatoPredcit was validated for deceased-donor transplantations, for patients with a total tumour volume <500 cm3 and a tumour number no larger than 10, and in the absence of extra-hepatic invasion.
HepatoPredict is distributed by a select number of distributors. If you wish to become a distributor for a specific market, or if you wish to know which HepatoPredict distributor will operate in your region, please get in touch.
HepatoPredict is distributed in Europe by Biocartis.
We are conducting a series of retrospective validation studies in multiple geographies for liver transplantation and resection. If you wish that your center becomes involved in these studies, please get in touch.